Paul W A Janssen1,2, Thomas O Bergmeijer3,4, Gert-Jan A Vos3,4, Johannes C Kelder3,4, Khalid Qaderdan3,4, Thea C Godschalk3,4, Nicoline J Breet4,5, Vera H M Deneer4,6, Christian M Hackeng4,7, Jurriën M Ten Berg3,4. 1. Department of Cardiology, St Antonius Hospital, P/O Box 2500, 3432 EM, Nieuwegein, The Netherlands. p.janssen@antoniusziekenhuis.nl. 2. St Antonius Centre for Platelet Function Research, St Antonius Hospital, Nieuwegein, The Netherlands. p.janssen@antoniusziekenhuis.nl. 3. Department of Cardiology, St Antonius Hospital, P/O Box 2500, 3432 EM, Nieuwegein, The Netherlands. 4. St Antonius Centre for Platelet Function Research, St Antonius Hospital, Nieuwegein, The Netherlands. 5. Department of Cardiology, Gelre ziekenhuizen, Apeldoorn, The Netherlands. 6. Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands. 7. Department of Clinical Chemistry, St Antonius Hospital, Nieuwegein, The Netherlands.
Abstract
PURPOSE: The POPular Risk Score was developed for the selective intensification of P2Y12 inhibitor treatment with prasugrel instead of clopidogrel in patients undergoing non-urgent percutaneous coronary intervention (PCI) with stent implantation. This score is based on platelet reactivity (VerifyNow P2Y12 assay), CYP2C19 genotyping, and clinical risk factors. Our aim was to determine if the use of this score in clinical practice is associated with a reduction in thrombotic events without increasing bleeding events. METHODS: In a single-center prospective cohort study, patients with a high risk score were treated with prasugrel and patients with a low risk score with clopidogrel. The risk score-guided cohort was compared with a historic cohort of clopidogrel-treated patients. The endpoint consisted of all-cause death, myocardial infarction, stroke, or stent thrombosis during 1 year of follow-up. TIMI major and minor bleeding events were also analyzed. RESULTS: The guided cohort contained 1127 patients, 26.9% of whom were switched to prasugrel according to the POPular Risk Score. The historic cohort contained 893 patients. The incidence of the combined thrombotic endpoint was significantly lower in the guided cohort as compared with the historic cohort (8.4% versus 3.7%, p < 0.001). This strategy was safe with respect to bleeding (4.0% versus 1.3%, p < 0.001, for TIMI major or minor bleeding). Results were comparable after multivariate and propensity score matched and weighted analysis. CONCLUSION: Selective intensification of P2Y12 inhibitor treatment after non-urgent PCI based on the POPular Risk Score is associated with a reduction in thrombotic events without an increase in bleeding events.
PURPOSE: The POPular Risk Score was developed for the selective intensification of P2Y12 inhibitor treatment with prasugrel instead of clopidogrel in patients undergoing non-urgent percutaneous coronary intervention (PCI) with stent implantation. This score is based on platelet reactivity (VerifyNow P2Y12 assay), CYP2C19 genotyping, and clinical risk factors. Our aim was to determine if the use of this score in clinical practice is associated with a reduction in thrombotic events without increasing bleeding events. METHODS: In a single-center prospective cohort study, patients with a high risk score were treated with prasugrel and patients with a low risk score with clopidogrel. The risk score-guided cohort was compared with a historic cohort of clopidogrel-treated patients. The endpoint consisted of all-cause death, myocardial infarction, stroke, or stent thrombosis during 1 year of follow-up. TIMI major and minor bleeding events were also analyzed. RESULTS: The guided cohort contained 1127 patients, 26.9% of whom were switched to prasugrel according to the POPular Risk Score. The historic cohort contained 893 patients. The incidence of the combined thrombotic endpoint was significantly lower in the guided cohort as compared with the historic cohort (8.4% versus 3.7%, p < 0.001). This strategy was safe with respect to bleeding (4.0% versus 1.3%, p < 0.001, for TIMI major or minor bleeding). Results were comparable after multivariate and propensity score matched and weighted analysis. CONCLUSION: Selective intensification of P2Y12 inhibitor treatment after non-urgent PCI based on the POPular Risk Score is associated with a reduction in thrombotic events without an increase in bleeding events.
Authors: Victor L Serebruany; Steven R Steinhubl; Peter B Berger; Alex I Malinin; Deepak L Bhatt; Eric J Topol Journal: J Am Coll Cardiol Date: 2005-01-18 Impact factor: 24.094
Authors: Donald E Cutlip; Stephan Windecker; Roxana Mehran; Ashley Boam; David J Cohen; Gerrit-Anne van Es; P Gabriel Steg; Marie-angèle Morel; Laura Mauri; Pascal Vranckx; Eugene McFadden; Alexandra Lansky; Martial Hamon; Mitchell W Krucoff; Patrick W Serruys Journal: Circulation Date: 2007-05-01 Impact factor: 29.690
Authors: Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman Journal: N Engl J Med Date: 2007-11-04 Impact factor: 91.245
Authors: Dirk Sibbing; Olga von Beckerath; Albert Schömig; Adnan Kastrati; Nicolas von Beckerath Journal: Blood Coagul Fibrinolysis Date: 2007-06 Impact factor: 1.276
Authors: Bryan P Yan; Andrew E Ajani; Gishel New; Stephen J Duffy; Omar Farouque; James Shaw; Martin Sebastian; Robert Lew; Angela Brennan; Nick Andrianopoulos; Chris Reid; David J Clark Journal: Int J Cardiol Date: 2008-08-15 Impact factor: 4.164
Authors: Tabassome Simon; Céline Verstuyft; Murielle Mary-Krause; Lina Quteineh; Elodie Drouet; Nicolas Méneveau; P Gabriel Steg; Jean Ferrières; Nicolas Danchin; Laurent Becquemont Journal: N Engl J Med Date: 2008-12-22 Impact factor: 91.245
Authors: Stephen D Wiviott; Eugene Braunwald; Dominick J Angiolillo; Simha Meisel; Anthony J Dalby; Freek W A Verheugt; Shaun G Goodman; Ramon Corbalan; Drew A Purdy; Sabina A Murphy; Carolyn H McCabe; Elliott M Antman Journal: Circulation Date: 2008-08-31 Impact factor: 29.690
Authors: Francesco Franchi; Fabiana Rollini; Jose Rivas; Andrea Rivas; Malhar Agarwal; Maryuri Briceno; Mustafa Wali; Ahmed Nawaz; Gabriel Silva; Zubair Shaikh; Naji Maailiki; Latonya Been; Andres M Pineda; Siva Suryadevara; Daniel Soffer; Martin M Zenni; Theodore A Bass; Dominick J Angiolillo Journal: JACC Basic Transl Sci Date: 2020-03-25
Authors: Thomas O Bergmeijer; Alfi Yasmina; Gerrit J A Vos; Paul W A Janssen; Christian M Hackeng; Johannes C Kelder; Shefali S Verma; Marylyn D Ritchie; Li Gong; Teri E Klein; Anthonius de Boer; Olaf H Klungel; Jurriën M Ten Berg; Vera H M Deneer Journal: Genes (Basel) Date: 2020-09-11 Impact factor: 4.096